Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (61-70 of 247) with videos related to

Pageof 25
Sort By:
BMC Cancer|March 8, 2017
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPatricia M LoRusso, Jeffrey R Infante, Kevin B Kim, et al.
The Prostate|January 29, 2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancerDonald L Trump, Heather Payne, Kurt Miller, et al.
Cancer|February 17, 2018
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2David R Spigel, John D Hainsworth, Mathew J Joseph, et al.
Clinical Breast Cancer|July 25, 2008
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancerDenise A Yardley, Howard A Burris, Cindy P Farley, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2015
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancerNiall Tebbutt, Dusan Kotasek, Howard A Burris, et al.
Journal of Neuro-Oncology|June 18, 2016
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningiomaKent C Shih, Sajeel Chowdhary, Paul Rosenblatt, et al.
Investigational New Drugs|April 21, 2017
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
Clinical Breast Cancer|October 28, 2008
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancerDenise A Yardley, Howard A Burris, Lisa Simons, et al.
Clinical Lung Cancer|June 14, 2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancerDavid R Spigel, F Anthony Greco, Howard A Burris, et al.
Investigational New Drugs|October 23, 2014
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancerJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Pageof 25

Showing results (61-70 of 247) with videos related to

Sort By:
Pageof 25
BMC Cancer|March 8, 2017
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPatricia M LoRusso, Jeffrey R Infante, Kevin B Kim, et al.
The Prostate|January 29, 2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancerDonald L Trump, Heather Payne, Kurt Miller, et al.
Cancer|February 17, 2018
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2David R Spigel, John D Hainsworth, Mathew J Joseph, et al.
Clinical Breast Cancer|July 25, 2008
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancerDenise A Yardley, Howard A Burris, Cindy P Farley, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2015
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancerNiall Tebbutt, Dusan Kotasek, Howard A Burris, et al.
Journal of Neuro-Oncology|June 18, 2016
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningiomaKent C Shih, Sajeel Chowdhary, Paul Rosenblatt, et al.
Investigational New Drugs|April 21, 2017
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
Clinical Breast Cancer|October 28, 2008
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancerDenise A Yardley, Howard A Burris, Lisa Simons, et al.
Clinical Lung Cancer|June 14, 2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancerDavid R Spigel, F Anthony Greco, Howard A Burris, et al.
Investigational New Drugs|October 23, 2014
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancerJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Pageof 25